We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Joint Panel Recommends Relaxing Avandia Restrictions
FDA Joint Panel Recommends Relaxing Avandia Restrictions
June 6, 2013
A conflicted joint FDA advisory committee voted Thursday to ease restrictions on sales of GlaxoSmithKline’s (GSK) diabetes drug Avandia but stopped short of recommending removal of the drug’s strict risk evaluation and mitigation strategy (REMS) program.